Publisher Correction: The National Lung Matrix Trial of personalized therapy in lung cancer

<https://doi.org/10.1038/s41586-020-2656-3>

Correction to: *Nature* <https://doi.org/10.1038/s41586-020-2481-8>

Published online 15 July 2020

Check for updates

Gary Middleton, Peter Fletcher, Sanjay Popat, Joshua Savage, Yvonne Summers, Alastair Greystoke, David Gilligan, Judith Cave, Noelle O'Rourke, Alison Brewster, Elizabeth Toy, James Spicer, Pooja Jain, Adam Dangoor, Melanie Mackean, Martin Forster, Amanda Farley, Dee Wherton, Manita Mehmi, Rowena Sharpe, Tara C. Mills, Maria Antonietta Cerone, Timothy A. Yap, Thomas B. K. Watkins, Emilia Lim, Charles Swanton & Lucinda Billingham

In this Article, the description for the Supplementary Information file stated: "This file contains Pre-clinical rationale for triaging participants to genotype-matched targeted therapies in the NLMT.". However, the initial Supplementary Information file uploaded contained only the trial protocol and did not contain the rationale. The Supplementary Information file has now been replaced online, and the description has been updated to read: "This file contains pre-clinical rationale for triaging participants to genotype-matched targeted therapies in the NLMT and Protocol version 8.0, in use on 30 November 2019."

In addition, the first four sentences of the Acknowledgements section have been altered to read: 'The Investigators and Sponsor thank all the patients and their families who participated in this trial, as well as the NHS Trusts and staff and the members of the Trial Steering Committee, chaired by R. Kaplan **and including independent members K. Kerr, C. Dick, J. Paul and J. Wason**, who supported this trial. We thank our patient and public representatives, M. Baker on the Trial Steering Committee and T. Haswell on the Trial Management Group. **We are grateful for the support of the Trial Management Group, including G. Cook, A. Desai, A. Devaraj, D. Fennell, M. Griffiths, S. Janes, S. M. Lee, U. McDermott, A. Nicholson, P. Rehal, S. Subramaniam, P. Tanriere, Y. Wallis and D. White and for the support of principal investigators P. Shaw (Velindre Cancer Centre), C. Lewanski and D. Power (Imperial College Healthcare NHS Trust) and S. Danson (Weston Park Cancer Centre).** We thank all staff at the Cancer Research UK Clinical Trials Unit for their contributions to the trial, including A. Allen, K. Brock, L. Crack, K. Davies, K. James, S. Mee, I. Nutt and S. Ordish.